Publications by authors named "L Fazli"
Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective, the disease almost always develops resistance. Given that many enzalutamide-resistant tumors lack specific somatic mutations, there is strong evidence that epigenetic factors can cause enzalutamide resistance.
View Article and Find Full Text PDFProstate Cancer Risk Stratification by Digital Histopathology and Deep Learning.
JCO Clin Cancer Inform
June 2024
Article Synopsis
- Prostate cancer (PCa) is a complex disease requiring better risk assessment methods beyond current models, which often lead to inconsistent grading, particularly with Gleason scores.
- This study introduces a deep learning model that utilizes histopathology images alongside clinical data to improve risk stratification for treatment-naïve PCa patients undergoing radical prostatectomy.
- Results show that this machine learning approach outperformed traditional models, accurately reclassifying risk levels for a notable percentage of patients, and could potentially enhance treatment planning with further validation.
Graph convolutional neural networks have shown significant potential in natural and histopathology images. However, their use has only been studied in a single magnification or multi-magnification with either homogeneous graphs or only different node types. In order to leverage the multi-magnification information and improve message passing with graph convolutional networks, we handle different embedding spaces at each magnification by introducing the Multi-Scale Relational Graph Convolutional Network (MS-RGCN) as a multiple instance learning method.
View Article and Find Full Text PDF